# Biocon gets US FDA approval for fifth cancer biosimilar Pebrilzo

2026-11-16T06:34:01+00:00 | Business & Economy | Indian Opinion Desk

Corroboration: 2 independent outlets
Outlets counted: business-standard.com, cnbctv18.com

Biocon has received US Food and Drug Administration approval for Pebrilzo (pertuzumab-qcay), a biosimilar to Genentech's Perjeta used in HER2-positive breast cancer. It is the company's fifth oncology biosimilar to clear the US FDA, adding to its portfolio of Ogivri, Jobevne, Fulphila and Aukelso. The drug is indicated with trastuzumab and chemotherapy for early-stage and metastatic disease. Biocon has entered a global settlement with Genentech securing the earliest licensed US launch date in the third quarter of calendar year 2028. In September, the European Medicines Agency's expert committee recommended marketing approval for Pebrilzo in Europe across multiple disease stages. The label carries warnings about cardiac risk and fetal harm, requiring regular monitoring and contraception during treatment. CEO Shreehas Tambe said the approval strengthens the anti-cancer portfolio and advances the company's commitment to affordable biologic medicines. Biocon's pipeline includes biosimilars to trastuzumab/hyaluronidase, nivolumab and pembrolizumab. Shares were trading 0.15 percent lower at ₹363.50 on Monday.

## Indian Opinion Analysis

Both Business Standard and CNBC-TV18 report identically on the regulatory win, Biocon's fifth biosimilar, and the licence deal setting a Q3 2028 US entry. Where they differ is in emphasis: Business Standard leads with the approval and its pipeline significance, and quotes CEO Shreehas Tambe on patient financial strain. CNBC-TV18 leads with the stock move, adds share price data, and includes safety warnings from the label. The overlapping core facts mean the coverage is uniform on the substance. The only open point is whether the stock movement reflects market disappointment over the 2028 launch window, which CNBC-TV18 hints at with the day's slight fall of 0.15 percent at ₹363.50.

## Coverage

Coverage: 2 sources, 2 neutral
- business-standard.com (neutral report) <https://www.business-standard.com/companies/news/biocon-secures-us-fda-approval-for-pebrilzo-its-fifth-cancer-biosimilar-126111600687_1.html>
  Leads with the approval and patient access, no market angle
- cnbctv18.com (neutral report) <https://www.cnbctv18.com/market/biocon-share-price-usfda-approval-pebrilzo-fifth-oncology-biosimilar-her2-positive-breast-cancer-drug-20034624.htm>
  Leads with stock gain, adds share price and safety warnings

This brief was synthesised by AI from the 2 sources linked above, so one read covers every framing they carry.

Tags: Biocon, Pebrilzo, Shreehas Tambe, US FDA
Canonical: https://indianopinion.org/biocon-gets-us-fda-approval-for-fifth-cancer-biosimilar-pebrilzo/
License: Summary and commentary (c) Indian Opinion, reusable with attribution. Facts belong to the linked sources.
Cite: https://indianopinion.org/biocon-gets-us-fda-approval-for-fifth-cancer-biosimilar-pebrilzo/#story-in-brief
Gate decision: pass (pass: linked qualifying outlets 2 of 2, relevance 8)
Freshness: pass (fresh: newest qualifying source 2026-11-16 05:23Z (feed), 1.2 h old)
Image: photograph. Source: https://bsmedia.business-standard.com/_media/bs/img/article/2021-08/10/thumb/featurecrop/1200X628/1628593401-9675.jpg.

How this brief was made: an AI model read the reports linked above and wrote this summary and analysis, which were published automatically. Published briefs are sampled every hour by an automated quality check; the editor verifies its findings and approves corrections, and corrected briefs carry a dated correction line. Stance labels are editorial classifications of how each outlet framed this story, assigned by the same model, not ratings of the outlets. We do no original reporting. Methodology: https://indianopinion.org/ai-use-policy/
